You have full text access to this OnlineOpen article

Cancer

Cover image for Vol. 116 Issue 23

1 December 2010

Volume 116, Issue 23

Pages 5341–5564

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
    2. You have free access to this content
      Marine microbes make a splash (page 5342)

      Carrie Printz

      Article first published online: 23 NOV 2010 | DOI: 10.1002/cncr.25780

    3. You have free access to this content
    4. You have free access to this content
  2. Commentaries

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have full text access to this OnlineOpen article
      Recent trends and future directions in human immunodeficiency virus-associated cancer (pages 5344–5347)

      Meredith S. Shiels, James J. Goedert and Eric A. Engels

      Article first published online: 19 OCT 2010 | DOI: 10.1002/cncr.25705

      Malignancies, including the 3 that are part of the definition of the acquired immunodeficiency syndrome (AIDS) (Kaposi sarcoma [KS], non-Hodgkin lymphoma [NHL], and cervical cancer) as well as certain non-AIDS–defining cancers, cause significant morbidity and an estimated 33% of the deaths reported among patients infected with the human immunodeficiency virus (HIV). The US Multicenter AIDS Cohort Study (MACS) analysis highlighted several interesting and important trends in AIDS-defining and non-AIDS–defining cancers among individuals infected with HIV.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have full text access to this OnlineOpen article
      The prevalence and assessment of ErbB2-positive breast cancer in Asia : A literature survey (pages 5348–5357)

      Yew Oo Tan, Sehwan Han, Yen-Shen Lu, Cheng-Har Yip, Patrapim Sunpaweravong, Joon Jeong, Priscilla B. Caguioa, Shyam Aggarwal, Ee Min Yeoh and Hanlim Moon

      Article first published online: 16 AUG 2010 | DOI: 10.1002/cncr.25476

      The reported prevalence of human epidermal growth factor receptor 2 (ErbB2)-positive tumors in Asia varied widely, in part because of the lack of standard, reliable testing methods. When only robust methods were considered, the prevalence of ErbB2-positive tumors in Asia was similar to that in Western countries.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. Disease Site

      Breast Disease
      You have full text access to this OnlineOpen article
      The frameshift polymorphism CYP3A43_74_delA is associated with poor differentiation of breast tumors (pages 5358–5364)

      Christina Justenhoven, Stefan Winter, Ute Hamann, Susanne Haas, Hans-Peter Fischer, Beate Pesch, Thomas Brüning, Yon-Dschun Ko, Hiltrud Brauch and for the GENICA Network

      Article first published online: 16 AUG 2010 | DOI: 10.1002/cncr.25508

      CYP3A43 is involved in the metabolism of steroid hormones. The authors observed an association between the CYP3A43 74 del A polymorphism and grade of breast tumors (odds ratio, 1.74; Ptrend = .012). The variant allele may lead to increased steroid hormone levels promoting growth of tumor cells and hinder differentiation.

    2. You have full text access to this OnlineOpen article
      Predictors of competing mortality in early breast cancer (pages 5365–5373)

      Loren K. Mell, Jong-Hyeon Jeong, Michael A. Nichols, Blase N. Polite, Ralph R. Weichselbaum and Steven J. Chmura

      Article first published online: 24 AUG 2010 | DOI: 10.1002/cncr.25370

      Noncancer (competing) mortality is an important event determining disease-free survival in early breast cancer. Black race, comorbid illness, and advanced age significantly increase the risk of this event; implications for designing clinical trials in patients at high risk for competing mortality are discussed.

    3. Gastrointestinal Disease
      You have full text access to this OnlineOpen article
      Prognostic value of lymph node evaluation in small bowel adenocarcinoma : Analysis of the surveillance, epidemiology, and end results database (pages 5374–5382)

      Michael J. Overman, Chung-Yuan Hu, Robert A. Wolff and George J. Chang

      Article first published online: 16 AUG 2010 | DOI: 10.1002/cncr.25324

      Survival after surgical resection of stage I, II, and III small bowel adenocarcinoma was associated significantly with the total number of assessed lymph nodes. Stratifying patients with stage III disease into those with <3 positive lymph nodes and ≥3 positive lymph nodes further improved prognostication.

    4. Genitourinary Disease
      You have full text access to this OnlineOpen article
      Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab (pages 5383–5390)

      Jorge A. Garcia, Thomas E. Hutson, Paul Elson, C. Lance Cowey, Timothy Gilligan, Cheryl Nemec, Robert Dreicer, Ronald M. Bukowski and Brian I. Rini

      Article first published online: 30 AUG 2010 | DOI: 10.1002/cncr.25327

      Administration of sorafenib is safe and feasible in patients with metastatic renal cell carcinoma refractory to either bevacizumab or sunitinib.

    5. You have full text access to this OnlineOpen article
      How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? (pages 5391–5399)

      Claire F. Snyder, Kevin D. Frick, Amanda L. Blackford, Robert J. Herbert, Bridget A. Neville, Michael A. Carducci and Craig C. Earle

      Article first published online: 23 AUG 2010 | DOI: 10.1002/cncr.25517

      This study examined the short-term and long-term costs of prostate cancer treatment based on the initial treatment received for 13,769 men diagnosed with clinically localized prostate cancer. Patterns of costs varied widely based on initial treatment; 5-year total costs were $26,896 for hormonal therapy only, $25,097 for hormonal therapy plus radiation, $19,214 for surgery, $15,589 for radiation only, and $9130 for watchful waiting.

    6. You have full text access to this OnlineOpen article
      Sunitinib rechallenge in metastatic renal cell carcinoma patients (pages 5400–5406)

      Ivan N. Zama, Thomas E. Hutson, Paul Elson, James M. Cleary, Toni K. Choueiri, Daniel Y.C. Heng, Nikhil Ramaiya, M. Dror Michaelson, Jorge A. Garcia, Jennifer J. Knox, Bernard Escudier and Brian I. Rini

      Article first published online: 2 NOV 2010 | DOI: 10.1002/cncr.25583

      The optimal clinical approach to the treatment-resistant renal cell carcinoma patient was unknown, and requires careful prospective trials for further insight. Sunitinib rechallenge had potential benefits in metastatic renal cell carcinoma patients. Prospective studies to evaluate this strategy were needed.

    7. Gynecologic Oncology
      You have full text access to this OnlineOpen article
      Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? : A Gynecologic Oncology Group ancillary data analysis (pages 5407–5414)

      Kathleen N. Moore, Chunqiao Tian, D. Scott McMeekin, J. Tate Thigpen, Marcus E. Randall and Holly H. Gallion

      Article first published online: 24 AUG 2010 | DOI: 10.1002/cncr.25480

      Time to recurrence after primary chemotherapy is predictive of survival after recurrence in advanced endometrial cancer. However, there is no evidence that this variable provides significant prognostic information or can be used in selecting salvage chemotherapy.

    8. You have full text access to this OnlineOpen article
      A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma (pages 5415–5419)

      Brian M. Slomovitz, Karen H. Lu, Taren Johnston, Robert L. Coleman, Mark Munsell, Russell R. Broaddus, Cheryl Walker, Lois M. Ramondetta, Thomas W. Burke, David M. Gershenson and Judith Wolf

      Article first published online: 2 AUG 2010 | DOI: 10.1002/cncr.25515

      Everolimus is an oral rapamycin analog that acts by selectively inhibiting mammalian target of rapamycin, an intracellular protein downstream to phosphatase and tensin homolog (PTEN) that helps to regulate cell growth and proliferation. Everolimus demonstrated an encouraging single-agent clinical benefit response rate in pretreated patients with recurrent endometrioid endometrial cancer.

    9. Hematologic Malignancies
      You have full text access to this OnlineOpen article
      Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome : A dose and schedule finding study (pages 5420–5431)

      Marcos de Lima, Sergio Giralt, Peter F. Thall, Leandro de Padua Silva, Roy B. Jones, Krishna Komanduri, Thomas M. Braun, Hoang Q. Nguyen, Richard Champlin and Guillermo Garcia-Manero

      Article first published online: 29 JUL 2010 | DOI: 10.1002/cncr.25500

      Azacitidine may decrease the disease recurrence rate after allogeneic transplants for advanced acute myelogenous leukemia or myelodysplastic syndrome. The authors determined that the maximum tolerated dose is 32 mg/m2 for 5 days, in monthly cycles.

    10. You have full text access to this OnlineOpen article
      Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma (pages 5432–5439)

      Richard R. Furman, Peter Martin, Jia Ruan, Ying-Kuen K. Cheung, Julie M. Vose, Ann S. LaCasce, Rebecca Elstrom, Morton Coleman and John P. Leonard

      Article first published online: 27 JUL 2010 | DOI: 10.1002/cncr.25509

      In vitro studies have suggested that bortezomib can enhance the efficacy of chemotherapy. This phase 1 study demonstrated that bortezomib at a dose of 1.3 mg/m2 twice per cycle can be added to the regimen of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with acceptable toxicity.

    11. Hepatobiliary Disease
      You have full text access to this OnlineOpen article
      Overexpression of CD151 as an adverse marker for intrahepatic cholangiocarcinoma patients (pages 5440–5451)

      Xiao-Yong Huang, Ai-Wu Ke, Guo-Ming Shi, Zhen-Bin Ding, Ranjan Prasad Devbhandari, Fang-Ming Gu, Quan-Lin Li, Zhi Dai, Jian Zhou and Jia Fan

      Article first published online: 16 AUG 2010 | DOI: 10.1002/cncr.25485

      CD151, as hydrophobic protein, interacts with other tetraspanins and with a variety of transmembrane and cytosolic proteins to form tetraspanin-enriched microdomains, which act as signaling platforms in the plasma membrane. The current results indicated that CD151 has potential as a novel marker for predicting the prognosis of patients with intrahepatic cholangiocarcinoma and may be a potential therapeutic target.

    12. You have full text access to this OnlineOpen article
      Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma : A randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization (pages 5452–5460)

      Manabu Morimoto, Kazushi Numata, Masaaki Kondou, Akito Nozaki, Satoshi Morita and Katsuaki Tanaka

      Article first published online: 29 JUL 2010 | DOI: 10.1002/cncr.25314

      The authors conducted a randomized controlled trial to evaluate the advantages of combining radiofrequency ablation (RFA) with transcatheter arterial chemoembolization (TACE) for treating patients with intermediate-sized (3.1-5.0 cm) hepatocellular carcinomas. The results showed that the local tumor progression rate in the TACE-RFA group was lower than that in the RFA group; however, there was no statistical difference between the overall survival rates and safety in the 2 groups.

    13. Neuro-Oncology
      You have full text access to this OnlineOpen article
      Dysembryoplastic neuroepithelial tumors and cognitive outcome : Cure at a price? (pages 5461–5469)

      Ibrahim Qaddoumi, David W. Ellison, E. Brannon Morris, Alberto Broniscer, Frederick Boop, Thomas Merchant, Shawna L. Palmer and Amar Gajjar

      Article first published online: 29 JUL 2010 | DOI: 10.1002/cncr.25528

      Data were reviewed regarding dysembryoplastic neuroepithelial tumors. The recurrence and progression rates of dysembryoplastic neuroepithelial tumors and the high rate of abnormal neurocognitive test results noted in this study highlight the need for regular follow-up and appropriate academic counseling of children with these tumors.

    14. Sarcoma
      You have full text access to this OnlineOpen article
      Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma (pages 5470–5478)

      David M. Loeb, Robert F. Hobbs, Amarachukwu Okoli, Allen R. Chen, Steve Cho, Senthamizhchelvan Srinivasan, George Sgouros, Ori Shokek, Moody D. Wharam Jr, Tammy Scott and Cindy L. Schwartz

      Article first published online: 16 AUG 2010 | DOI: 10.1002/cncr.25518

      Tandem doses of samarium-153 ethylenediamine tetramethylene phosphoric acid can be safely administered to heavily pretreated patients with high-risk osteosarcoma. There is a linear relationship between administered activity and tumor absorbed dose within each evaluable patient.

    15. You have full text access to this OnlineOpen article
      Radiation-induced sarcoma in patients with nasopharyngeal carcinoma : A single-institution study (pages 5479–5486)

      Mian Xi, Meng-Zhong Liu, Hai-Xia Wang, Ling Cai, Li Zhang, Chun-Fang Xie and Qiao-Qiao Li

      Article first published online: 16 AUG 2010 | DOI: 10.1002/cncr.25329

      The results from this retrospective study confirmed the rarity and poor prognosis of radiation-induced sarcoma in patients with nasopharyngeal carcinoma. The only independent predictive factor that was associated with better survival was complete surgical resection.

    16. Discipline

      Disparities Research
      You have full text access to this OnlineOpen article
      Stage of breast cancer at diagnosis among low-income women with access to mammography (pages 5487–5496)

      Rebecca Lobb, John Z. Ayanian, Jennifer D. Allen and Karen M. Emmons

      Article first published online: 31 AUG 2010 | DOI: 10.1002/cncr.25331

      Programs ensuring that breast cancer screening and diagnostic services are available at no cost to low-income women can mitigate the adverse effect of area-level poverty on stage of breast cancer. However, such programs require effective strategies to encourage use of screening mammography to promote diagnosis at an earlier stage.

    17. You have full text access to this OnlineOpen article
      Quality of cancer care among foreign-born and US-born patients with lung or colorectal cancer (pages 5497–5506)

      Signe Smith Nielsen, Yulei He, John Z. Ayanian, Scarlett Lin Gomez, Katherine L. Kahn, Dee W. West and Nancy L. Keating

      Article first published online: 29 JUL 2010 | DOI: 10.1002/cncr.25546

      Foreign-born patients with lung or colorectal cancer in the United States reported a lower quality of care and were less likely to receive some recommended cancer therapies than US-born patients. These differences were partly explained by English language proficiency.

    18. Epidemiology
      You have full text access to this OnlineOpen article
      Cancer incidence in the multicenter aids cohort study before and during the HAART era : 1984 to 2007 (pages 5507–5516)

      Eric C. Seaberg, Dorothy Wiley, Otoniel Martínez-Maza, Joan S. Chmiel, Lawrence Kingsley, Yiwei Tang, Joseph B. Margolick, Lisa P. Jacobson and for the Multicenter AIDS Cohort Study (MACS)

      Article first published online: 29 JUL 2010 | DOI: 10.1002/cncr.25530

      Since the introduction of highly active antiretroviral therapy (HAART) in the mid-1990s, the incidence of Kaposi sarcoma and non-Hodgkin lymphoma in people infected with the human immunodeficiency virus (HIV) has dropped dramatically. A decade later, however, HIV infection remains significantly associated with an elevated risk of these cancers, Hodgkin lymphoma, and anal cancer.

    19. Pathology
      You have full text access to this OnlineOpen article
      Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy (pages 5517–5526)

      Luciana Schultz, Roula Albadine, Jessica Hicks, Sana Jadallah, Angelo M. DeMarzo, Ying-Bei Chen, Matthew E. Neilsen, Mark L. Gonzalgo, David Sidransky, Mark Schoenberg and George J. Netto

      Article first published online: 11 OCT 2010 | DOI: 10.1002/cncr.25502

      Mammalian target of rapamycin pathway was overall down-regulated in urothelial carcinoma. Phosphorylated S6 protein was an independent predictor of disease-specific survival, and c-myc was an independent predictor of progression.

      Corrected by:

      Erratum: Erratum

      Vol. 117, Issue 21, 5021, Article first published online: 11 APR 2011

    20. Psychosocial Oncology
      You have full text access to this OnlineOpen article
      Increased risk of severe depression in male partners of women with breast cancer (pages 5527–5534)

      Naoki Nakaya, Kumi Saito-Nakaya, Pernille Envold Bidstrup, Susanne Oksbjerg Dalton, Kirsten Frederiksen, Marianne Steding-Jessen, Yosuke Uchitomi and Christoffer Johansen

      Article first published online: 27 SEP 2010 | DOI: 10.1002/cncr.25534

      This cohort study supported the hypothesis that the male partners of women with breast cancer are at a significantly increased risk for hospitalization with affective disorders. Results concluded that a diagnosis of breast cancer not only affects the life of the patient but may also seriously affect their partner.

    21. Translational Research
      You have full text access to this OnlineOpen article
      22-Oxa-1,25-dihydroxyvitamin D3 efficiently inhibits tumor growth in inoculated mice and primary histoculutre of cholangiocarcinoma (pages 5535–5543)

      Wunchana Seubwai, Chaisiri Wongkham, Anucha Puapairoj, Seiji Okada and Sopit Wongkham

      Article first published online: 2 AUG 2010 | DOI: 10.1002/cncr.25478

      22-Oxa-dihydroxyvitamin D3(22-oxa-D3), an analog of vitamin D, significantly inhibited the growth of cholangiocarcinoma (CCA) cell lines in a time-dependent and dose-dependent manner, and the treatment arrested cells in G1 phase to S phase by reducing the expression of cyclin D1 and increasing the expression of p21. The antitumor activity of 22-oxa-D3 was strongly demonstrated in CCA-inoculated mice and in histoculutured tissues from patients with CCA.

    22. You have full text access to this OnlineOpen article
      Cationic polymer-mediated small interfering RNA delivery for P-glycoprotein down-regulation in tumor cells (pages 5544–5554)

      Meysam Abbasi, Afsaneh Lavasanifar, Luc G. Berthiaume, Michael Weinfeld and Hasan Uludağ

      Article first published online: 16 AUG 2010 | DOI: 10.1002/cncr.25321

      Multidrug resistance is among the major causes of limited chemotherapy efficiency in cancer cells. The results from this study indicated that effective small interfering RNA delivery with nonviral polymeric carriers can reduce the level of permeability glycoprotein on cell surfaces and enhance the efficiency of chemotherapeutic agents in vitro.

    23. Symptom Control and Palliative Care
      You have full text access to this OnlineOpen article
      Risk of mortality in patients with cancer who experience febrile neutropenia (pages 5555–5563)

      Gary H. Lyman, Shannon L. Michels, Matthew W. Reynolds, Rich Barron, Karen Smoyer Tomic and Jingbo Yu

      Article first published online: 16 AUG 2010 | DOI: 10.1002/cncr.25332

      Febrile neutropenia (FN) is a potentially life-threatening condition in patients with cancer who receive chemotherapy. In this study, crude and adjusted mortality rates were greater for patients who had FN compared with controls for all tumor types.

  5. Correspondence

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have full text access to this OnlineOpen article
    2. You have full text access to this OnlineOpen article

SEARCH

SEARCH BY CITATION